Table 2.
The candidates of COVID-19 mucosal vaccine in clinical.
| Type of vaccine | Name | Antigen | Carrier | Administration | Status | NCT |
|---|---|---|---|---|---|---|
| Ad-vectored vaccine | Ad5-nCoV | Spike protein | Ad | Inhale | Phase Ⅲ | NCT04540419 |
| Ad-vectored vaccine | hAd5-S-Fusion | Spike protein | Oral capsule | p.o. | Phase Ⅰ/Ⅱ | NCT04845191 |
| Live attenuated vaccine | DelNS1-2019-nCoV-RBDOPT1 | RBD domain of S protein | Influenza virus (CA4-DelNS1) | Inhale | Phase II | ChiCTR2000039715 |
| Live attenuated vaccine | COVI-VAC | SARS-CoV-2 | / | Inhale | Phase Ⅰ | NCT04619628 |
| Ad-vectored vaccine | AdCOVID | RBD domain of S protein | Ad5 | Inhale | Phase Ⅰ | NCT04679909 |
| BBV154 | Spike protein | Ad | i.n. | Phase Ⅰ | NCT04751682 | |
| ChAdOx1 nCOV-19 | Spike protein | Ad | i.n. | Phase Ⅰ | NCT04816019 |
Ad, adenovirus; p.o., oral administration; i.n., intranasal administration.